Sandra K Baril, M.D.
Investigator
Dr. Sandra K. Baril is a Pediatric Hematology and Oncology physician with Sutter Medical Group in Sacramento, CA. She completed her fellowship at Vanderbilt Children’s Hospital, where she also served as a Research Fellow in the Rathmell Lab, investigating genomic integrity and mechanisms of chemotherapy resistance. Dr. Baril earned her medical degree cum laude from St. George’s University and completed her pediatrics residency at Geisinger Medical Center. She is board certified by the American Board of Pediatrics. Dr. Baril is an active member of Children’s Oncology Group and serves as the Institutional Principal Investigator for SMCS. She is dedicated to delivering compassionate, evidence-based care to children and families
Clinical trials
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Hodgkin Lymphoma COG AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Neuroblastoma ANBL2131
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Pediatric Leukemia AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse.
Status: Open to Enrollment
- Clinical trial
Pediatric B-Lymphoblastic Leukemia COG AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy
Status: Open to Enrollment